Our analysis indicates that industry's contributions to the R&D of innovative drugs go beyond development and marketing and include basic and applied science, discovery technologies, and manufacturing protocols, and that without private investment in the applied sciences there would be no return on public investment in basic science.

No abstract

No abstract

Medicare's decision to restrict coverage of florbetapir, a diagnostic agent for Alzheimer's disease, exemplifies an inconsistent approach to technology evaluation. Joshua Cohen and colleagues call for consistency Joshua P Cohen research associate professor 1 , Jinghui Dong research associate 1 , Christine Y Lu instructor 2 , Ranjana Chakravarthy research analyst Center for the Study of Drug Development, for her help with our literature search and discussion of the Amyvid/florbetapir case.